CN103479711A - Application of eucommia ulmoides lignans extracts in preparation of medicine treating renal interstitial fibrosis - Google Patents
Application of eucommia ulmoides lignans extracts in preparation of medicine treating renal interstitial fibrosis Download PDFInfo
- Publication number
- CN103479711A CN103479711A CN201310423484.6A CN201310423484A CN103479711A CN 103479711 A CN103479711 A CN 103479711A CN 201310423484 A CN201310423484 A CN 201310423484A CN 103479711 A CN103479711 A CN 103479711A
- Authority
- CN
- China
- Prior art keywords
- cortex eucommiae
- mass concentration
- methanol
- lignans extract
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000284 extract Substances 0.000 title claims abstract description 57
- 229930013686 lignan Natural products 0.000 title claims abstract description 50
- 235000009408 lignans Nutrition 0.000 title claims abstract description 50
- 150000005692 lignans Chemical class 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 239000003814 drug Substances 0.000 title claims abstract description 12
- 241000208689 Eucommia ulmoides Species 0.000 title abstract 4
- 206010023421 Kidney fibrosis Diseases 0.000 title abstract 2
- ZJSJQWDXAYNLNS-UHFFFAOYSA-N (+) pinoresinol-4,4'-di-O-beta-D-glucopyranoside Natural products COC1=CC(C2C3C(C(OC3)C=3C=C(OC)C(OC4C(C(O)C(O)C(CO)O4)O)=CC=3)CO2)=CC=C1OC1OC(CO)C(O)C(O)C1O ZJSJQWDXAYNLNS-UHFFFAOYSA-N 0.000 claims abstract description 9
- ZJSJQWDXAYNLNS-FUPWJLLWSA-N (2s,3r,4s,5s,6r)-2-[4-[(3s,3ar,6s,6ar)-6-[3-methoxy-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan-3-yl]-2-methoxyphenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound COC1=CC([C@@H]2[C@@H]3[C@@H]([C@H](OC3)C=3C=C(OC)C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=CC=3)CO2)=CC=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZJSJQWDXAYNLNS-FUPWJLLWSA-N 0.000 claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 47
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 42
- 210000003734 kidney Anatomy 0.000 claims description 32
- 206010016654 Fibrosis Diseases 0.000 claims description 14
- 230000004761 fibrosis Effects 0.000 claims description 14
- 239000011347 resin Substances 0.000 claims description 13
- 229920005989 resin Polymers 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 238000010828 elution Methods 0.000 claims description 9
- 239000004615 ingredient Substances 0.000 claims description 7
- 230000001476 alcoholic effect Effects 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 230000000274 adsorptive effect Effects 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 239000012567 medical material Substances 0.000 claims description 3
- 238000005520 cutting process Methods 0.000 claims description 2
- 239000004033 plastic Substances 0.000 claims description 2
- 229920003023 plastic Polymers 0.000 claims description 2
- 239000000470 constituent Substances 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 18
- 238000004043 dyeing Methods 0.000 description 13
- 230000008595 infiltration Effects 0.000 description 12
- 238000001764 infiltration Methods 0.000 description 12
- 210000004969 inflammatory cell Anatomy 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 238000000034 method Methods 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 238000004611 spectroscopical analysis Methods 0.000 description 6
- 210000005239 tubule Anatomy 0.000 description 6
- JDZYVVUJIQYGRX-UHFFFAOYSA-N 1-(3-fluorophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC(F)=C1 JDZYVVUJIQYGRX-UHFFFAOYSA-N 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000017074 necrotic cell death Effects 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 210000000626 ureter Anatomy 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000031816 Pathologic Dilatation Diseases 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 201000002793 renal fibrosis Diseases 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000001913 cellulose Chemical class 0.000 description 2
- 229920002678 cellulose Chemical class 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- -1 electuary Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000009525 mild injury Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229960002275 pentobarbital sodium Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical class O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Chemical class OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical class OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Chemical class 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 241000208688 Eucommia Species 0.000 description 1
- 241000208686 Eucommiaceae Species 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000022461 Glomerular disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical class OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical class OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Chemical class OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003035 anti-peroxidant effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical class OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000008103 glucose Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000008101 lactose Chemical class 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Chemical class OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008807 pathological lesion Effects 0.000 description 1
- 230000004796 pathophysiological change Effects 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Chemical class 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Chemical class 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Chemical class 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical class OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to the field of purposes of extracts of traditional Chinese medicine, in particular to application of eucommia ulmoides lignans extracts in preparation of medicine treating renal interstitial fibrosis. Lignans accounts for 30-90% of the total weight of the eucommia ulmoides lignans extracts, and the effective constituent of pinoresinol diglucoside in the lignans accounts for 1%-15% of the total weight of the eucommia ulmoides lignans extracts.
Description
Technical field
The invention belongs to Chinese medicine extract purposes field, be specifically related to the new purposes of Cortex Eucommiae lignans extract.
Background technology
Renal fibrosis is a kind of pathophysiological change, be the function of kidney by health to damage, then to damaging, until the progressive process of afunction.Consequently the irreversible infringement of carrying out property of renal function, bring huge threat to human health.Kidney region fibrosis is the common pathological characters that kidney disease advances to renal failure in whole latter stage due to a variety of causes.Clinical and pathological data show in a large number, and the Chronic Renal Injury that a variety of causes causes and the order of severity of kidney region fibrosis change to than glomerulopathy closely.Therefore, in order to slow down and reverse the process of chronic renal disease, improve renal function, find and the active drug that finds the treatment renal fibrosis for guiding clinical treatment, to improve nephrotic quality of life significant.
The dry bark that the Cortex Eucommiae is the Eucommiaceae plant Cortex Eucommiae is Chinese famous and precious tonic herb.Tool invigorating the liver and kidney, bone and muscle strengthening, blood pressure lowering, many effects such as antiabortive, it is Chinese peculiar medical material, its medicinal history is long, clinical, has a wide range of applications.The Cortex Eucommiae has invigorating the liver and kidney, and rubbish in body is removed in bone and muscle strengthening, strengthen the human body cell substance metabolism, prevent that muscle skeleton is aging, the balance human blood-pressure, the decomposer inner cholesterol, reduce body fat, recover blood vessel elasticity, the diuresis heat clearing away, broad-spectrum antiseptic, stimulating central nervous system, improve white blood cell count, strengthens the remarkable efficacy such as body immunity.The effective ingredient of the Cortex Eucommiae mainly contains lignanoid, iridoids, flavonoid, organic acid, alcohol, trace element, vitamin etc., and lignanoid is one of composition that in the Cortex Eucommiae, content is maximum.Cortex Eucommiae lignanoid has the pharmacological actions such as blood pressure lowering, anti peroxidation of lipid, protection central nervous system.
Less to the pharmacological research of Cortex Eucommiae lignans extract both at home and abroad at present.Application number: 200710035744.7 disclose Cortex Eucommiae lignanoid and the application of extract on anti-cardiovascular reconstruction thereof, and the new purposes of Cortex Eucommiae lignans extract remains further to be studied.
Summary of the invention
Purpose of the present invention aims to provide a kind of new purposes of Cortex Eucommiae lignans extract.We study and find that Cortex Eucommiae lignans extract has preventive and therapeutic effect to kidney region fibrosis, can be used for the medicine of preparation treatment kidney region fibrosis.
For achieving the above object, technical scheme of the present invention is:
The application of Cortex Eucommiae lignans extract in preparation treatment kidney region fibrosis medicine, in described Cortex Eucommiae lignans extract, lignanoid accounts for the 30%-90% of Cortex Eucommiae lignans extract gross weight, and in lignanoid, the content of effective ingredient pinoresinol diglucoside accounts for the 1%-15% of Cortex Eucommiae lignans extract gross weight.
In described lignanoid, the content of effective ingredient pinoresinol diglucoside preferably accounts for the 3%-7.5% of Cortex Eucommiae lignans extract gross weight.
Described Cortex Eucommiae lignans extract preferably be take the Cortex Eucommiae as raw material, the alcohol extraction that is 40%-95% by mass concentration, extracting liquid filtering, concentrated, concentrated solution is passed through to macroporous resin column, water successively, the methanol that mass concentration is 15%-25% or ethanol, the methanol that mass concentration is 45%-55% or alcoholic solution eluting, the alcohol eluen that the collection mass concentration is 45%-55%, concentrated, drying, obtain Cortex Eucommiae lignans extract powder.
The preferred preparation method of described Cortex Eucommiae lignans extract is:
A) after Cortex Eucommiae removes crust, the alcoholic solution reflux, extract, that cutting is 40%-95% by mass concentration 2-3 time, each 1-2h, extracting solution is evaporated to 0.5-1.5 times of medical material amount volume;
B) medicinal liquid after concentrating is carried out to the effective ingredient enrichment by macroporous adsorptive resins, water successively, the methanol that mass concentration is 15%-25% or ethanol, the methanol that mass concentration is 45%-55% or alcoholic solution eluting;
C) collect methanol or the ethanol elution that mass concentration is 45%-55%, concentrated, the dry Cortex Eucommiae lignans extract powder that obtains.
Collect the water elution liquid in step b, concentrated, dry, pulverize, the powder dissolve with methanol, discard insoluble matter, reclaims methanol the dry iridoids material that obtains.
Macroporous adsorptive resins described in step b is HP series plastics, D101 resin or AB-8 resin.
Cortex Eucommiae lignans extract of the present invention can be also the disclosed Cortex Eucommiae lignans extract of number of patent application 200710035744.7.
Below the present invention is further explained and illustrates.
Described Cortex Eucommiae lignans extract can be selected from pulverizing by employing, squeezes, calcines, grinds, sieves, percolation, extraction, water extraction, alcohol extraction, water precipitating, precipitate with ethanol, ester are carried, the methods such as ketone is carried, chromatography, filtration obtain.Take this extract can be made into pharmaceutical preparation as active substance, and described extract can be the material of extractum form, can be that dry extract can be also fluid extract, can be powdered substance, according to the difference of preparation, need to make different states.
The present invention also proposes the pharmaceutical preparation of Cortex Eucommiae lignans extract through applicable any unit dosage form of taking of processing preparation, these pharmaceutical preparatioies are selected from following dosage form: tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, suck agent, granule, electuary, pill, powder, unguentum, sublimed preparation, suspensoid, powder, solution, suppository, ointment, plaster, cream, spray, drop, patch, while needing, can make slow releasing preparation, enteric coated preparation.
Cortex Eucommiae lignans extract of the present invention, can add the medicine acceptable carrier when being prepared into pharmaceutical preparation, described medicine acceptable carrier is selected from: antioxidant, intercalating agent surfactant filler disintegrating agent wetting agent dispersant lubricant solvent slow release material enteric material pH adjusting agent, correctives, pigment etc., carrier commonly used is as mannitol, dextran, lactose, glucose, sorbitol, mannitol, xylitol, sodium chloride, silicon derivative, cellulose and cellulose derivative, sodium sulfite, sodium pyrosulfite, alginate, gelatin, polyvinylpyrrolidone, glycerol, Tween 80, agar, calcium carbonate, calcium bicarbonate, Polyethylene Glycol, cyclodextrin, beta-schardinger dextrin-, the phospholipid material, Kaolin, Pulvis Talci, calcium stearate, magnesium stearate etc.
The pharmaceutical preparation of Cortex Eucommiae lignans extract of the present invention is by Cortex Eucommiae raw material being processed through extraction or other modes, being made pharmaceutically active substance, subsequently, take this active substance as raw material, add the medicine acceptable carrier while needing, according to the routine techniques of galenic pharmacy, make pharmaceutical preparation.
The accompanying drawing explanation
Fig. 1 is the normal optical spectroscopy figure (numbering: 1M12) after rats in sham-operated group kidney HE dyeing; HE dyeing, * 200; Glomerule.The renal tubules form is normal, and interstitial has no the congestion of blood vessel, the variations such as inflammatory cell infiltration.
Fig. 2 is the normal optical spectroscopy figure (numbering: 2M11) after model group rat kidney HE dyeing.HE dyeing, * 200.Glomerule.The renal tubules structure disappears, a large amount of proliferations of fibrous tissue of interstitial, and with a large amount of inflammatory cell infiltrations.
Fig. 3 is the normal optical spectroscopy figure (numbering: 3M06) after the low dose group rat kidney HE of Cortex Eucommiae lignanoid dyeing.HE dyeing, * 200.The renal cells degeneration necrosis, the part tubule dilatation, a large amount of proliferations of fibrous tissue of interstitial, and with a large amount of inflammatory cell infiltrations.
Fig. 4 is the normal optical spectroscopy figure (numbering: 4M02) after dosage group rat kidney HE dyeing in Cortex Eucommiae lignanoid.HE dyeing, * 200.The renal cells degeneration necrosis, the part tubule dilatation, a small amount of proliferation of fibrous tissue of interstitial, and with a small amount of inflammatory cell infiltration.
Fig. 5 is the normal optical spectroscopy figure (numbering: 5M05) after the high dose group rat kidney HE of Cortex Eucommiae lignanoid dyeing.HE dyeing, * 200.The renal cells degeneration necrosis, the part tubule dilatation, a small amount of proliferation of fibrous tissue of interstitial, and with a small amount of inflammatory cell infiltration.
Fig. 6 is the normal optical spectroscopy figure (numbering: 6M02) after Fluorofenidone positive controls rat kidney HE dyeing.HE dyeing, * 200.The renal cells degeneration necrosis, a small amount of proliferation of fibrous tissue of interstitial, and with a small amount of inflammatory cell infiltration.
The specific embodiment
Below by embodiment, the present invention will be further explained, and percentage composition described in embodiment is the quality percentage composition.
The preparation of embodiment 1 Cortex Eucommiae lignans extract
Get eucommia bark (removing crust) 2Kg, with 8L65% alcohol reflux twice, each 1h, filter, and merges extracted twice liquid and be concentrated into 800ml.Mix sample loading (macroporous resin column volume 3L) with the D101 macroporous resin, wash 3 times of column volumes, 1% ammonia continues to wash 3 times of column volumes, then is washed to neutrality.With 2 times of column volumes of 20% ethanol elution, with 45% ethanol, wash 2.5 times of column volumes.45% ethanol elution is concentrated into 600ml.Be dried to powder after eluent is concentrated.With pinoresinol diglucoside in contrast, Cortex Eucommiae lignans extract is 85% through ultraviolet detection lignans content, and detecting pinoresinol diglucoside content through HPLC is 12.5%.
The preparation of embodiment 2 Cortex Eucommiae lignans extracts
Cortex Eucommiae (removing crust) adds 60% ethanol 9L reflux, extract, 1h after pulverizing, and filters, and filtering residue adds 60% ethanol 7L again and extracts 1h, filters, and merges extracted twice liquid, is concentrated into without the alcohol flavor, obtains the about 3L of concentrated solution.Concentrated solution, through the AB-8 macroporous adsorptive resins, is first used the 5L water elution, then uses the 7L60% ethanol elution, collects 60% ethanol elution, is concentrated into 150ml, slowly is added in 450ml water, filters, concentrated, obtains the drying solid powder.With pinoresinol diglucoside in contrast, Cortex Eucommiae lignans extract is 51% through ultraviolet detection lignans content, and detecting pinoresinol diglucoside content through HPLC is 3.5%.
Embodiment 3
Embodiment 1 and the resulting Cortex Eucommiae lignans extract of embodiment 2 are studied for the Protection to kidney region fibrosis of embodiment 3.
1. experimental technique
1.1 dosage design and grouping
Experiment is divided into sham operated rats, model group, Cortex Eucommiae lignans extract low dose group (150mg/kg), middle dosage group (300mg/kg), high dose group (600mg/kg) and Fluorofenidone positive controls (500mg/kg).
Table 1 test grouping and dosage design
1.2 experimental procedure
60 of male SD rats, body weight 250～300g, the surgical ligation group adopts unilateral ostruction, method is as follows: press 2mL/kg lumbar injection 2% pentobarbital sodium anesthetized rat, aseptic condition is in the about 1.5cm of abdominal part left kidney position otch, kidney is extruded gently, peel off gently left side ureter surrounding tissue with ophthalmic tweezers, expose ureter, with sterilizing stitching thread ligation ureter, separately get 12 rats as sham operated rats, modus operandi is identical, and kidney is extruded to rear separation left side ureter but not ligation gently.After above animal surgery completes, suture muscles, skin successively, wound surrounding injection 100,000 U penicillins are in case infect.60 ligation group rats were carried out to the eye socket blood sampling in the 3rd day after surgery, separation of serum, detect serum creatinine and urea nitrogen content, result shows that surgical ligation group serum creatinine and urea nitrogen content raise, according to the index result, the surgical ligation group is divided into to 5 groups at random, every group 12, be respectively model group, the basic, normal, high dosage group of Cortex Eucommiae lignans extract and Fluorofenidone positive controls.Before every day experiment by the Cortex Eucommiae for lignans extract distilled water, Fluorofenidone according to dosage be mixed with respective concentration with 0.5%CMC-Na, now with the current, press the 10mL/kg gastric infusion, 1 times/day, continuous 15 days.Sham operated rats and model group give isopyknic distilled water.After pressing 2mL/kg lumbar injection 2% pentobarbital sodium anesthetized rat euthanasia after the last administration, dissection is got nephridial tissue and is fixed, and paraffin embedding, carry out tissue pathology checking.
1.3 detection index
The kidney morphologic observation: getting respectively rat kidney, to be placed in 10% neutral formalin liquid fixing, and conventional dehydration, embedding, section, HE dyeing, carry out histopathologic examination.Pathology integration standard: tubulointerstitial injury is marked, and the random selection of each specimen does not repeat 10 visuals field, comprises cortex, medullary substance, skin marrow intersection, comprises 6 specific targets: (1) tubular ectasia; (2) renal tubules atrophy; (3) the renal cells cavity forms; (4) the renal cells cavity forms; (5) kidney region fibrosis; (6) kidney interstitial inflammatory cell infiltration, the focal type cell infiltration of kidney interstitial is the mild damage; The inflammatory cell infiltration that diffusivity is dispersed in is the moderate infringement; The intensive inflammatory cell infiltration of diffusivity is the severe infringement.Each project is divided into to 0 minute according to the degree of pathological lesion: normal; 1 minute: mild damage's (pathological changes is less than 20%); 2 minutes: moderate infringement (pathological changes 20%～40%); 3 minutes: severe infringement (pathological changes is greater than 40%).
1.4 statistical method:
Adopt SPSS16.0 to carry out statistical analysis, the level set of statistical significance is P<0.05.Adopt mean ± standard deviation
use Leven ' s test method check normality and homogeneity of variance.If meet normality and homogeneity of variance, with one factor analysis of variance (One-way ANOVA) and post Hoc LSD, carry out statistical analysis; If do not meet normality and heterogeneity of variance, check with Kruskal-Wallis.If Kruskal-Wallis check has statistical significance (P<0.05), use Dunnett ' s Test(nonparametric technique) compare analysis.Consider significant difference and biological significance during evaluation.
2 experimental results
The impact of Cortex Eucommiae lignans extract on nephropathy Neo-Confucianism
As shown in table 2 and Fig. 1-6, with normal control, to compare, tubular ectasia, atrophy appear in the model group rat kidney, renal cells necrosis, the inflammatory cell infiltration that kidney region fibrosis and diffusivity are intensive.From the statistical result of average pathology integration, can find out, model group pathology integration is significantly higher than sham operated rats, prompting renal fibrosis model modeling success.After administration 15 days, Cortex Eucommiae lignans extract high dose group and Fluorofenidone positive controls are compared and significant difference all occurred with model group, and there is a change for the better for kidney region fibrosis.
Table 2 Cortex Eucommiae lignans extract is on the pathological impact of kidney region fibrosis
Annotate: with sham operated rats, compare,
++p<0.01, compare with model group,
*p<0.05.
3 experiment brief summaries
The above results shows, Cortex Eucommiae lignans extract high dose group can significantly be improved tubular ectasia, the atrophy of kidney region fibrosis model, and the symptoms such as kidney interstitial inflammatory cell infiltration, have some improvement to kidney region fibrosis.
Claims (6)
1. the application of Cortex Eucommiae lignans extract in preparation treatment kidney region fibrosis medicine, in described Cortex Eucommiae lignans extract, lignanoid accounts for the 30%-90% of Cortex Eucommiae lignans extract gross weight, and in lignanoid, the content of effective ingredient pinoresinol diglucoside accounts for the 1%-15% of Cortex Eucommiae lignans extract gross weight.
2. application according to claim 1, is characterized in that, in described lignanoid, the content of effective ingredient pinoresinol diglucoside accounts for the 3%-7.5% of Cortex Eucommiae lignans extract gross weight.
3. according to the described application of claim 1 or 2, it is characterized in that, described Cortex Eucommiae lignans extract is to take the Cortex Eucommiae as raw material, the alcohol extraction that is 40%-95% by mass concentration, extracting liquid filtering, concentrated, concentrated solution is passed through to macroporous resin column, water successively, the methanol that mass concentration is 15%-25% or ethanol, the methanol that mass concentration is 45%-55% or alcoholic solution eluting, the alcohol eluen that the collection mass concentration is 45%-55%, concentrated, drying, obtain Cortex Eucommiae lignans extract powder.
4. application according to claim 4, is characterized in that, the preparation method of described Cortex Eucommiae lignans extract is:
A) after Cortex Eucommiae removes crust, the alcoholic solution reflux, extract, that cutting is 40%-95% by mass concentration 2-3 time, each 1-2h, extracting solution is evaporated to 0.5-1.5 times of medical material amount volume;
B) medicinal liquid after concentrating is carried out to the effective ingredient enrichment by macroporous adsorptive resins, water successively, the methanol that mass concentration is 15%-25% or ethanol, the methanol that mass concentration is 45%-55% or alcoholic solution eluting;
C) collect methanol or the ethanol elution that mass concentration is 45%-55%, concentrated, the dry Cortex Eucommiae lignans extract powder that obtains.
5. apply according to claim 4, it is characterized in that, collect the water elution liquid in step b, concentrated, dry, pulverize, the powder dissolve with methanol, discard insoluble matter, reclaims methanol the dry iridoids material that obtains.
6. application according to claim 4, is characterized in that, macroporous adsorptive resins described in step b is HP series plastics, D101 resin or AB-8 resin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310423484.6A CN103479711B (en) | 2013-09-17 | 2013-09-17 | Application of eucommia ulmoides lignans extracts in preparation of medicine treating renal interstitial fibrosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310423484.6A CN103479711B (en) | 2013-09-17 | 2013-09-17 | Application of eucommia ulmoides lignans extracts in preparation of medicine treating renal interstitial fibrosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103479711A true CN103479711A (en) | 2014-01-01 |
| CN103479711B CN103479711B (en) | 2015-05-13 |
Family
ID=49820527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310423484.6A Active CN103479711B (en) | 2013-09-17 | 2013-09-17 | Application of eucommia ulmoides lignans extracts in preparation of medicine treating renal interstitial fibrosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103479711B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105250352A (en) * | 2015-10-20 | 2016-01-20 | 欧阳冬生 | Application of eucommia ulmoides lignan extract in preparation of PH (pulmonary hypertension) treatment drug |
| CN110538189A (en) * | 2019-09-22 | 2019-12-06 | 江西普正制药股份有限公司 | Eucommia ulmoides extract composition for treating renal fibrosis and application thereof |
| CN111202741A (en) * | 2020-01-21 | 2020-05-29 | 中南大学湘雅医院 | Application of lignan compound in preparation of medicine for treating and/or preventing nephropathy |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102643610A (en) * | 2011-02-16 | 2012-08-22 | 严晓敏 | Production method for extracting natural polymer material from eucommia pericarp |
-
2013
- 2013-09-17 CN CN201310423484.6A patent/CN103479711B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102643610A (en) * | 2011-02-16 | 2012-08-22 | 严晓敏 | Production method for extracting natural polymer material from eucommia pericarp |
Non-Patent Citations (2)
| Title |
|---|
| 韩宇东: "《内蒙古中医药》", 《杜仲药理活性研究进展》, no. 4, 28 February 2011 (2011-02-28), pages 125 - 126 * |
| 骆小娟等: "《杜仲对单侧输尿管梗阻大鼠肾间质纤维化的影响》", 《山东医药》, vol. 52, no. 28, 31 December 2012 (2012-12-31), pages 47 - 48 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105250352A (en) * | 2015-10-20 | 2016-01-20 | 欧阳冬生 | Application of eucommia ulmoides lignan extract in preparation of PH (pulmonary hypertension) treatment drug |
| CN110538189A (en) * | 2019-09-22 | 2019-12-06 | 江西普正制药股份有限公司 | Eucommia ulmoides extract composition for treating renal fibrosis and application thereof |
| CN111202741A (en) * | 2020-01-21 | 2020-05-29 | 中南大学湘雅医院 | Application of lignan compound in preparation of medicine for treating and/or preventing nephropathy |
| CN111202741B (en) * | 2020-01-21 | 2021-07-20 | 中南大学湘雅医院 | Application of lignan compound in preparation of medicine for treating and/or preventing nephropathy |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103479711B (en) | 2015-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104844723B (en) | A kind of preparation method and application of Herba Dendrobii extract | |
| CN101161251B (en) | Teasel root total saponin as well as its extracting method and application | |
| CN103479711B (en) | Application of eucommia ulmoides lignans extracts in preparation of medicine treating renal interstitial fibrosis | |
| CN101011452A (en) | Plant extract with hypotensive effect and its preparing process and use | |
| CN108743795B (en) | Korean medicine extract for preventing and treating diabetic nephropathy and preparation method and application thereof | |
| CN101677989A (en) | A drug composition for treatment and prevention of ischemic stroke and its preparation methods | |
| CN101428050B (en) | Active composition for treating thrombus, cardio-cerebrovascular system diseases | |
| CN103893283A (en) | Traditional Chinese medicine composition for treatment of chronic renal diseases and chronic renal failure and its preparation method and use | |
| CN100509009C (en) | A Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and ischemic apoplexy, and its preparation method | |
| CN1250253C (en) | Chinese medicine capsule for treating ischemic cerebral apoplexy | |
| CN1771978A (en) | Notoginseng triol-saponin composition and its prepn and use | |
| CN104116752B (en) | The application of aucubin in preparation treatment kidney region fibrosis medicine | |
| CN101152234B (en) | Application of cortex eucommiae lignans and its extract in against cardiovascular reconstruction | |
| CN100484566C (en) | Chinese medicine preparation for heat-clearing, dampness-removing, diuresis and stone removing and its preparation | |
| CN113144020A (en) | Traditional Chinese medicine composition for treating arthralgia, preparation method thereof and traditional Chinese medicine preparation | |
| CN1939417B (en) | Medicinal composition of douricine, tinosporae or its extract | |
| CN103705772B (en) | Chinese medicine composition that a kind of antiinflammatory protects the liver and preparation method thereof | |
| CN103893286B (en) | It is a kind of to treat Chinese medicine preparation of chronic renal disease and preparation method thereof | |
| CN102861192B (en) | Medicine composition for chronic renal failure and peritoneal fibrosis | |
| CN1660163A (en) | Method for extracting general iridoid glycoside from 'Duyiwei' of Tibet medicine and application | |
| CN101474315B (en) | Effective component group of stem-bark or root-bark of Daphne giraldii as well as preparation method and use thereof | |
| CN111068024A (en) | Chinese medicine compound preparation and its preparing method | |
| CN107320528A (en) | A kind of Chinese medical extract and medicine for treating alpastic anemia | |
| CN112569313B (en) | Traditional Chinese medicine composition for treating nephropathy | |
| CN101926848B (en) | Medicinal composition for treating heart cerebrovascular diseases and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20161220 Address after: 411000 Hunan province Changsha high tech Development Zone, Lu Tin Road No. 28, No. 601, C8-C10 building science and Technology Park Lugu Patentee after: Changsha are biological technology Co., Ltd. Address before: 410078 Hunan province Changsha Kaifu District, Xiangya Road No. 110 clinical pharmacology research institute of Central South University Patentee before: Ouyang Dongsheng |
|
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: Room 601, building c8-c10, jinruilugu science and Technology Park, No.28 Lutian Road, high tech Development Zone, Changsha City, Hunan Province, 410000 Patentee after: Changsha Duzheng Biotechnology Co., Ltd Address before: 411000 Hunan province Changsha high tech Development Zone, Lu Tin Road No. 28, No. 601, C8-C10 building science and Technology Park Lugu Patentee before: CHANGSHA DUXACT BIOTECH Co.,Ltd. |